Navigation Links
Dendreon Reports Third Quarter 2007 Financial Results
Date:11/15/2007

- Management Will Host Conference Call at 1:30 PM ET -

SEATTLE, Nov. 15 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2007. Revenue for the third quarter of 2007 was $112,000 compared to $84,000 for the quarter ended September 30, 2006. Revenue for the nine months ended September 30, 2007 was $715,000 compared to $187,000 for the nine months ended September 30, 2006.

Dendreon's total operating expenses for the third quarter of 2007 were $19.8 million compared to $21.7 million in 2006. Dendreon's total operating expenses for the nine months ended September 30, 2007 were $75.2 million compared to $73.6 million for the same period in 2006.

The net loss for the quarter ended September 30, 2007 was $19.2 million, or $0.23 per share, compared to a net loss of $20.7 million, or $0.29 per share, for the quarter ended September 30, 2006. The net loss for the nine months ended September 30, 2007 was $72.3 million, or $0.88 per share, compared to $70.2 million, or $0.98 per share for the nine months ended September 30, 2006.

Cash, cash equivalents and short-term and long-term investments at September 30, 2007 totaled $138.8 million compared to $121.3 million at December 31, 2006.

Recent Highlights:

-- Completed enrollment of over 500 patients in the Phase 3 IMPACT

(IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as

D9902B) clinical trial of PROVENGE(R) (sipuleucel-T). Dendreon

received confirmation that the FDA will accept either a positive

interim or positive final analysis of overall survival from the IMPACT

study to amend the Biologics License App
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)... , Feb. 26, 2015   Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... , Ph.D., President and Chief Executive Officer of Regulus, ... Company 35 th Annual Healthcare Conference on Wednesday, ... is being held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... 2015  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), ... and hair rejuvenation, has announced that it has ... for investor relations and strategic communications. ... and diversification strategies – and we need to ... stated Ali Kharazmi CEO of NuGene when announcing ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... Company, FRAZER, Pa., Feb. 8 Cephalon, Inc., ... Counsel &,Secretary, John E. Osborn, has decided to resign ... has agreed to remain as an advisor,to the company ... been an invaluable member of our senior executive team ...
... REDWOOD CITY, Calif., Feb. 8 Genomic Health,Inc. (Nasdaq: ... Health,s,President and Chief Operations Officer, will present at the ... Feb. 12, 2008 at 10:15 a.m. Eastern,Time., To ... visit the Investor Relations section of Genomic Health,s,website at ...
... InterMune, Inc.,(Nasdaq: ITMN ) today announced results from operations ... company also provided 2008,financial guidance and milestones for its key ... InterMune reported a net loss for the fourth quarter of ... net loss of $21.5 million, or,$0.64 per share, in the ...
Cached Biology Technology:Cephalon General Counsel John E. Osborn to Resign Position 2Cephalon General Counsel John E. Osborn to Resign Position 3InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 2InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 3InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 4InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 5InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 6InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 7InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 8InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 9InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 10InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 11
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... date of 130 North American tree species concludes that ... northward by hundreds of kilometers and shrink the ranges ... McKenney of the Canadian Forest Service and his colleagues, ... McKenneys study is based on an extensive data-gathering effort ...
... Trust researchers have identified a key gene involved in the ... mostly women. The lead researcher behind the study has called ... to further study the underlying causes of the disease. ... autoimmune disease which frequently causes skin rash, joint pains and ...
... able to differentiate metastatic cancer cells from normal cells ... softness of the cells. The study, published Dec. ... journal Nature Nanotechnology, represents one of the first times ... cancer patients and apply nanotechnology to analyze them and ...
Cached Biology News:Climate change predicted to drive trees northward 2Lupus gene finding prompts call for more DNA samples 2Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 2Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 3Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 4
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Anti-Human alpha2-Antiplasmin Purified (Polyclonal) (goat IgG)...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
... The Mini-PROTEAN 3 Dodeca cell with multi-casting chamber ... up to 12 mini format handcast (8.3 x ... gels. The cell requires 3.4-4.4 L of buffer ... coil that attaches to an external refrigerated circulator ...
Biology Products: